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Abstract
We examined whether quantitative bioﬁlm formation and/or
lipopolysaccharide type of Burkholderia pseudomallei was associated
with relapsing melioidosis. We devised a 1 : 4 nested case–control
study in which both cases and controls were drawn from a cohort
of patients with primary melioidosis. Paired isolates from 80
patients with relapse and single isolates from 184 patients without
relapse were tested. Relapse was associated with bioﬁlm forma-
tion of the primary infecting isolate (conditional OR 2.03;
95% CI 1.27–3.25; p 0.003), but not with lipopolysaccharide type
(p 0.74). This ﬁnding highlights the importance of bioﬁlm forma-
tion in relapsing melioidosis.
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Introduction
Melioidosis, an infectious disease caused by the Tier 1 select
agent Burkholderia pseudomallei, is notoriously difﬁcult to cure
[1]. North-eastern Thailand is a hot spot for this infection,
with an annual incidence of 21.0 per 100 000 population and a
case-fatality rate of 40% [2]. For patients who survive their ﬁrst
episode of infection, the single most important complication is
recurrent melioidosis following apparent cure. This occurs in
approximately 13% of patients followed for 10 years, and half
of the recurrences occur within 12 months of the primary
episode [3]. Approximately one-quarter of those with relapse
will die as a direct result [4,5].
Bioﬁlm formation has been described as an important factor
associated with persistent infections in a number of infectious
diseases, including Burkholderia cepacia infection in cystic
ﬁbrosis patients [6–8], but this has not been formally evaluated
in relation to relapse of melioidosis. A previous study of a small
number of isolates associated with relapse suggested that
B. pseudomallei with uncommon lipopolysaccharide (LPS) types
(smooth type B and rough type) might be associated with
relapse [9]. Here, we evaluated bioﬁlm formation and LPS type
of B. pseudomallei isolates from patients with primary melioi-
dosis drawn from a cohort described previously [5], and
determined their associations with relapse.
We devised a 1 : 4 nested case–control study in which both
cases and controls were drawn from a cohort of patients with
primary melioidosis identiﬁed between 1986 and 2004 who
survived to receive oral antimicrobial therapy and were
observed until July 2005 [5]. Cases were all patients who
developed at least one episode of relapse during the study
period, with relapse being veriﬁed by genotyping of the
primary and relapse isolates [5]. Controls were randomly
selected from those patients in the cohort who had not
developed relapse by the time relapse was identiﬁed in cases.
Cases and controls were matched for known risk factors for
relapse, including choice and duration of oral antimicrobial
therapy, positive blood culture, and multifocal distribution of
infection at ﬁrst presentation. Primary isolates from cases and
controls and relapse isolates from cases were evaluated for
quantitative bioﬁlm formation and LPS. All isolates were stored
at 80°C prior to the evaluation. The ﬁrst isolate cultured and
saved from each episode was used in the study. Quantitative
estimation of bioﬁlm formation was performed with a modiﬁed
microtitre plate test, as described previously [10–12]. All
experiments were independently conducted twice, and the
results reported were the average from those two exper-
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iments. LPS was extracted, and the type was deﬁned as smooth
type A, smooth type B, or rough type, as described previously
[9]. A conditional logistic regression model was used to
evaluate the relationships between independent factors and
the relapse outcome. Selection of controls and statistical
analyses were conducted with STATA, version 12.0 (Stata-
Corp, College Station, TX, USA). The study was approved by
the Ethical and Scientiﬁc review subcommittee of the Thai
Ministry of Public Health [5].
Of 86 and 202 primary isolates from cases and matched
controls, 80 (93%) and 184 (91%), respectively, were available
for study and included in the analysis. Patients in the case and
control groups had comparable characteristics for the
matched variables (Table 1).
First, we determined whether the quantitative production
of bioﬁlm by the primary isolate inﬂuenced the likelihood that
relapse would occur. Bioﬁlm production by primary isolates
from patients with relapse was higher than that for primary
isolates from matched patients without relapse (median
corrected optical density (OD)630 nm of 0.95 (interquartile
range 0.75–1.28) vs. 0.79 (interquartile range 0.63–1.06)). This
was independently associated with the relapse outcome
(conditional OR 2.03; 95% CI 1.27–3.25; p 0.003). Overall,
99% of primary isolates from cases and 98% from controls had
LPS smooth type A. LPS smooth type B was found in one (1%)
case and in two (1%) controls, and rough-type LPS was found
in one (1%) control. An association between LPS type of the
primary isolate and relapse was not found (p 0.74).
Next, we determined whether there was any difference in
bioﬁlm formation and in LPS type between primary and relapse
isolates from the same relapse cases. From 80 relapse cases, 71
(89%) paired primary–relapse isolates were available and eval-
uated. Bioﬁlm formation of the primary isolate and that of the
relapse isolate were not different (mean difference for corrected
OD630 nm of 0.002; 95% CI 0.16 to 0.16; p 0.98). The LPS type
of the primary–relapse pair was the same for all 71 isolates (LPS
smooth type A, n = 70; LPS smooth type B, n = 1).
In this study, we have shown that a quantitative measure of
bioﬁlm formation by the primary isolate is associated with
relapse in patients with melioidosis. This was independent of
known clinical risk factors for relapse, including choice and
duration of oral antimicrobial therapy, positive blood culture,
and multifocal distribution of infection at ﬁrst presentation,
factors that were matched by the nested case–control study
design. This provides the ﬁrst evidence to suggest that bioﬁlm
formation of B. pseudomallei in vitro is associated with relapse in
human melioidosis, and is consistent with ﬁndings reported for
Escherichia coli [6] and other bioﬁlm-producing bacteria [7,8]. We
also observed that quantitative bioﬁlm formation did not differ
between paired primary and relapse isolates. This lack of
detectable change between isolates of the same lineage that are
separated by the period spanning human infection, quiescence
and re-emergence argues against the notion that increased
bioﬁlm formation occurs in vivo through positive selection.
Quantitative bioﬁlm formation by isolates in this study was
lower overall than that reported previously for 34 clinical
B. pseudomallei isolates (mean corrected OD630 nm of
1.98  0.32) [12]. Possible explanations are that the means
used in the previous study were skewed by isolates with
exceptionally high bioﬁlm formation. In addition, the isolates in
the study described here were only from patients who
survived the ﬁrst episode of acute infection, whereas the
isolates in the previous study included those who died during
the acute infection.
The majority of B. pseudomallei isolates from the primary
episode of melioidosis in this study expressed LPS smooth
type A, and no association between LPS type and relapse was
found. This contrasts with the ﬁndings of a previous study, in
which three of 11 (27%) patients with recurrent melioidosis
had different LPS types in the primary and relapse isolates [9].
The ﬁnding in the previous study may relate to a small sample
size. Furthermore, isolates in this previous study were not
genotyped, and the possibility that recurrence was attributable
to re-infection with a different isolate rather than persistence
TABLE 1. Characteristics of cases and controls
Characteristics
Cases
N = 80
Controls
N = 184 p-Valuea
Median age in
years (interquartile
range)
49 (41–58) 47 (38–57) 0.47
Male sex, n (%) 53 (66) 104 (56) 0.32
Underlying
diseases, n (%)
Diabetes mellitus 49 (61) 103 (56) 0.24
Renal calculi 14 (18) 21 (11) 0.43
Distribution of melioidosisb, n (%)
Localized 27 (34) 64 (35) NA
Multifocal 13 (16) 29 (16)
Bacteraemic 23 (29) 56 (30)
Disseminated 17 (21) 35 (19)
Site or organ(s) infected during the primary episode, n (%)
Bacteraemia 40 (50) 91 (49) NA
Pneumonia 30 (38) 75 (41) 0.84
Liver abscess 24 (30) 45 (24) 0.28
Splenic abscess 29 (36) 54 (29) 0.50
Septic arthritis 8 (10) 19 (10) 0.67
Osteomyelitis 2 (3) 4 (2) 0.85
Bioﬁlm formation,
corrected OD630 nm
(interquartile range)
0.95 (0.75–1.28) 0.79 (0.63–1.06) 0.003
Bioﬁlm, n (%)
Smooth type A 79 (99) 181 (98) 0.74
Smooth type B 1 (1) 2 (1)
Rough type – 1 (1)
NA, not applicable, as choice and duration of oral antimicrobial therapy, positive
blood culture result and multifocal distribution of ﬁrst presentation were matched
variables; OD, optical density.
ap-Values were calculated with a conditional logistic regression model.
bMelioidosis was classiﬁed as localized (single focus of infection and a negative
blood culture result), multifocal (one or more non-contiguous foci of infection and
a negative blood culture result), bacteraemic (a positive blood culture result plus a
single or no identiﬁable focus of infection), and disseminated (a positive blood
culture result plus one or more non-contiguous foci of infection).
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and relapse with the primary isolate was not excluded [9]. The
proportions of uncommon, non-type A LPS in the primary
episode of melioidosis in this study (1% in cases and 2% in
controls) were similar to those observed in the previous study
(3%) [9]. Our ﬁndings, based on a much larger number of
bacterial isolates supported by a robust study design, do not
provide evidence for a link between uncommon, non-type A
LPS and relapse.
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